Peptron Registers Canadian Patent for MUC1-Specific Binding Antibody

[Asia Economy Reporter Lee Gwan-joo] Peptron announced on the 8th that it has received a patent registration decision from the Canadian Intellectual Property Office for the "Antibody Specifically Binding to Mucin1 (MUC1) and Its Use."

This patent acquisition marks the sixth following Korea, Australia, Russia, South Africa, and Japan. Additionally, applications are under examination in the United States, Europe, and various countries worldwide.

The patented PAb001 is Peptron's first new drug developed using its unique 'PepGen' technology, which induces antibodies targeting specific peptides (amino acid compounds). It binds to MUC1, a cancer cell-specific cell surface glycoprotein, penetrates into the cell, attacks cancer cells, and shows complete remission.

Peptron has utilized the patent to develop and license therapeutics for cancers caused by MUC1 overexpression. It has signed a technology transfer agreement with China's Qilu and is jointly developing next-generation CAR-NK immuno-oncology cell therapies with Therabest.

CEO Choi Ho-il stated, "Through the sequential acquisition of previously filed patents, we will strive this year to gradually produce results from our long-term efforts and enhance corporate value."

This content was produced with the assistance of AI translation services.